None listed
Conditions
Interventions
None listed
Sponsors
Gachon University Gil Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Type 2 diabetic patients diagnosed at the age of 30 or older - Aged 75 and younger - Patients with eGFR and albuminuria recordings at least three times in intervals of at least 3 months - Patients taking antihypertensive agents and angiotensin converting enzyme (ACE) inhibitor / angiotensin II receptor blocker (ARB) for hypertension or albuminuria have been receiving stable doses for more than 2 weeks As a healthy healthy control group, adult subjects who aged more than 30 and 75 or less years old, with neither diabetes nor chronic kidney disease
Exclusion criteria
Exclusion criteria: ? Under the age of 30 or over 75 years old ? Patients with type 1 diabetes or diabetic ketoacidosis ? Patients with CKD unrelated to diabetes ? Patients with poor blood pressure control or those taking 4 or more classes of antihypertensive drugs ? Patients with kidney transplantation or single kidney, patients with genetic kidney disease ? Among retrospective trajectory data, initial urine albumin/creation ratio (UACR)> 3500 mg/g, hemoglobin <11 g/dL, or serum albumin <3.6 g/dL ? Hemoglobin A1c level> 11.0% at enrollment, ? A history of dialysis or a history of acute kidney injury ? Other severe systemic disease or BMI <18.5 kg /square meters ? Pregnant women ? Malignant diseases with the last 5 years ? Long-term use (3 or more months) of nephrotoxic agents (e.g., NSAID and lithium) ? The use of Steroids(for 3 or more weeks) or systemic immunosuppressant dosage ? Patients who are considered inappropriate due to other clinical studies (eg, severe systemic disease, mental illness, social anxiety, etc.) ? End-stage renal disease before enrollment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MicroRNA profiles associated with the progression of diabetic nephropathy | — |
Secondary
| Measure | Time frame |
|---|---|
| Predictive performance of the combination of selected microRNA markers and clinical variables for progressive diabetic nephropathy | — |
Countries
Korea, Republic of
Contacts
Public ContactDAE HO LEE
Gachon University Gil Medical Center
Outcome results
None listed